__timestamp | Novo Nordisk A/S | Supernus Pharmaceuticals, Inc. |
---|---|---|
Wednesday, January 1, 2014 | 26760000000 | 72471000 |
Thursday, January 1, 2015 | 32169000000 | 89204000 |
Friday, January 1, 2016 | 32339000000 | 106010000 |
Sunday, January 1, 2017 | 32124000000 | 137905000 |
Monday, January 1, 2018 | 33313000000 | 159888000 |
Tuesday, January 1, 2019 | 35830000000 | 158425000 |
Wednesday, January 1, 2020 | 36886000000 | 200677000 |
Friday, January 1, 2021 | 41058000000 | 304759000 |
Saturday, January 1, 2022 | 50684000000 | 377221000 |
Sunday, January 1, 2023 | 61598000000 | 336361000 |
Monday, January 1, 2024 | 67377000000 |
Igniting the spark of knowledge
In the world of pharmaceuticals, strategic spending on Selling, General, and Administrative (SG&A) expenses can be a key differentiator. Novo Nordisk A/S, a global leader in diabetes care, and Supernus Pharmaceuticals, Inc., a specialist in central nervous system disorders, present a fascinating contrast in their SG&A spending from 2014 to 2023.
Novo Nordisk's SG&A expenses have surged by approximately 130% over the decade, reflecting its aggressive market expansion and robust R&D investments. In 2023, their SG&A spending reached a peak, highlighting their commitment to maintaining a competitive edge. Conversely, Supernus Pharmaceuticals, while smaller in scale, has shown a steady increase in SG&A expenses, growing by nearly 365% over the same period. This growth underscores their strategic focus on expanding their market presence and enhancing operational efficiency.
These spending patterns reveal the distinct strategies employed by each company to navigate the competitive pharmaceutical landscape.
Novo Nordisk A/S or Vertex Pharmaceuticals Incorporated: Who Manages SG&A Costs Better?
Cost Management Insights: SG&A Expenses for Novo Nordisk A/S and Genmab A/S
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or Sarepta Therapeutics, Inc.
Comparing SG&A Expenses: Novo Nordisk A/S vs ImmunityBio, Inc. Trends and Insights
Breaking Down SG&A Expenses: Novo Nordisk A/S vs Soleno Therapeutics, Inc.
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MorphoSys AG
Who Optimizes SG&A Costs Better? Novo Nordisk A/S or MannKind Corporation
SG&A Efficiency Analysis: Comparing Novo Nordisk A/S and HUTCHMED (China) Limited
SG&A Efficiency Analysis: Comparing Alnylam Pharmaceuticals, Inc. and Supernus Pharmaceuticals, Inc.
Genmab A/S and Supernus Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Perrigo Company plc and Supernus Pharmaceuticals, Inc.
Who Optimizes SG&A Costs Better? MorphoSys AG or Supernus Pharmaceuticals, Inc.